Antibody-drug conjugates: precision target therapeutics

Antibody-drug conjugates (ADCs) are an advanced class of biopharmaceuticals designed to selectively deliver potent cytotoxic agents to diseased cells. By combining the specificity of monoclonal antibodies with highly active small-molecule drugs, ADCs aim to maximize therapeutic efficacy while minimizing systemic toxicity.

This targeted approach has positioned ADCs as one of the most rapidly evolving modalities in oncology, with emerging exploration across autoimmune, CNS, endocrine, and infectious diseases.

Read the full infographic below

Please enter your email to access content Read now